The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts.
 
Mafalda Oliveira
Honoraria - AstraZeneca; Curio Science; Eisai; Gilead Sciences; i-One; Libbs; Lilly; MSD
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly; MSD; Pfizer; ProteinQure; Relay Therapeutics; Roche
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); Immutep (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Eisai; Gilead Sciences; Roche
(OPTIONAL) Uncompensated Relationships - President elected, SOLTI Cancer Research Group
 
Melissa Accordino
Honoraria - Incrowd
Research Funding - Genentech (Inst); Novartis (Inst); Roche (Inst)
Other Relationship - Disney
 
Andres Cervantes
Consulting or Advisory Role - Abbvie; Foundation Medicine (Inst); Merck Serono (Inst); Roche (Inst)
Research Funding - Actuate Therapeutics (Inst); Adaptimmune (Inst); Amcure (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Spain (Inst); Bayer (Inst); BeiGene (Inst); BMSi (Inst); FibroGen (Inst); Genentech (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Natera (Inst); Novartis (Inst); SERVIER (Inst); Sierra Oncology (Inst); Takeda (Inst)
Other Relationship - Annals of Oncology; Cancer Treatment Reviews; ESMO Open
 
Valentina Gambardella
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Amcure (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); FibroGen (Inst); Genentech (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Natera (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst); Sierra Oncology (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Erika Hamilton
Consulting or Advisory Role - Accutar Biotechnology (Inst); Arvinas (Inst); AstraZeneca (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Entos (Inst); Fosun Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Jefferies (Inst); Johnson and Johnson (Inst); Lilly (Inst); Medical Pharma Services (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Tempus (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst); Zentalis (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squib (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Inspirna (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Stemline Therapeutics (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
Komal Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Gilead Sciences; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Context Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); RayzeBio (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical
 
Dejan Juric
Consulting or Advisory Role - AstraZeneca, Eisai, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Mapkure, Novartis, Pfizer, Relay Therapeutics, Syros Pharmaceuticals, Vibliome
Research Funding - Amgen, Inc., AstraZeneca, Blueprint Medicines Corporation, Eisai, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Infinity Pharmaceuticals, Novartis, Pfizer, Ribon Therapeutics, Scorpion Therapeutics, Seagen, Inc., Syros, Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteus, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd (Basel, Switzerland).
 
Kevin Kalinsky
Employment - EQRx (I)
Stock and Other Ownership Interests - EQRx (I)
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; Gilead Sciences; Lilly; Menarini Silicon Biosystems; Merck; Mersana; mersana; Myovant Sciences; Novartis; Pfizer; Prelude Therapeutics; ProteinQure; Puma Biotechnology; RayzeBio; Regor; Relay Therapeutics; Takeda
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
 
Ian Krop
Employment - PureTech (I)
Leadership - PureTech (I)
Stock and Other Ownership Interests - PureTech (I)
Honoraria - AstraZeneca; Daiichi Sankyo
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genentech/Roche; Merck; Merck KGaA; Novartis; Seagen
Research Funding - Genentech (Inst); Macrogenics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - anti-murine CD19 monoclonal antibody licensed to PharMingen
 
Cristina Saura
Consulting or Advisory Role - AstraZeneca, Daiichi Sankyo, Eisai, Gilead Sciences, Lilly MediTech, Novartis, Pint Pharma, Pfizer, PharmaLex, Philips Healthcare, Pierre Fabre, Puma Biotechnology, Roche, SeaGen, Synthon, Zymeworks
Research Funding - AstraZeneca, Daiichi Sankyo, Eisai, Gilead Sciences, Novartis, Pfizer, Puma Biotechnology, Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca, Daiichi Sankyo, Eisai, Gilead Sciences, Novartis, Pfizer, Puma Biotechnology, Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteus, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd (Basel, Switzerland).
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Bayer; Boehringer Ingelheim; Celgene; Celgene; Eisai; Genentech (Inst); Gilead Sciences Hong Kong; Merck; Novartis; Oncogenex (Inst); Oncogenex (Inst); Pfizer; Puma Biotechnology; Roche; Sanofi; Stemline Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ESMO; SABS
 
Nicholas Turner
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Guardant Health; Inivata; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Relay Therapeutics; Repare Therapeutics; Roche
Research Funding - AstraZeneca (Inst); Guardant Health (Inst); Inivata (Inst); InVitae (Inst); Merck Sharpe and Dohme (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst); Roche (Inst)
 
Andrea Varga
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteus, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd (Basel, Switzerland).
 
Yanling Jin
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Samuel Lim
Employment - Genentech
Stock and Other Ownership Interests - F. Hoffmann-La Roche Ltf
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteus, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd (Basel, Switzerland).
 
Stephanie Royer-Joo
Employment - Genentech
Stock and Other Ownership Interests - Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteus, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd (Basel, Switzerland).
 
Noopur Shankar
Employment - Genentech
Stock and Other Ownership Interests - Roche/Genentech
Travel, Accommodations, Expenses - Genentech/Roche
 
Jennifer Schutzman
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Philippe Bedard
Honoraria - Boehringer Ingelheim
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bicara Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); LegoChem Biosciences (Inst); Lilly (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - Janssen Oncology; Lilly; Repare Therapeutics; Roche/Genentech; Seagen; Zymeworks